News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
698,591 Results
Type
Article (39683)
Company Profile (247)
Press Release (658661)
Multimedia
Podcasts (49)
Webinars (12)
Section
Business (204160)
Career Advice (2007)
Deals (35417)
Drug Delivery (95)
Drug Development (81048)
Employer Resources (172)
FDA (16179)
Job Trends (14857)
News (345176)
Policy (32536)
Tag
2024 BioCapital Digital (6)
2024 BioForest Digital (1)
2024 BioForest Standard (1)
2024 BioMidwest Digital (7)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (4)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (17)
2024 Biotech Beach Digital (8)
2024 Biotech Beach Standard (4)
2024 Genetown Digital (5)
2024 Genetown Standard (8)
2024 Lone Star Bio Digital (4)
2024 Pharm Country Digital (5)
2024 Pharm Country Standard (4)
2025 BioForest Digital (1)
2025 Lone Star Bio Digital (5)
2026 BioCapital Standard (1)
2026 BioMidwest Elite (1)
2026 Bio NC Standard (1)
2026 Biotech Bay Standard (1)
2026 Biotech Beach Elite (1)
2026 Genetown Elite (2)
2026 Genetown Standard (1)
2026 Pharm Country Standard (2)
Academia (2554)
Accelerated approval (5)
Adcomms (20)
Allergies (84)
Alliances (49427)
ALS (88)
Alzheimer's disease (1376)
Antibody-drug conjugate (ADC) (124)
Approvals (16185)
Artificial intelligence (250)
Autoimmune disease (21)
Automation (16)
Bankruptcy (360)
Best Places to Work (11637)
BIOSECURE Act (19)
Biosimilars (105)
Biotechnology (175)
Bladder cancer (77)
Brain cancer (27)
Breast cancer (278)
Cancer (2248)
Cardiovascular disease (173)
Career advice (1675)
Career pathing (30)
CAR-T (150)
Cell therapy (419)
Cervical cancer (19)
Clinical research (65971)
Collaboration (832)
Compensation (524)
Complete response letters (19)
COVID-19 (2588)
CRISPR (39)
C-suite (240)
Cystic fibrosis (100)
Data (2193)
Decentralized trials (2)
Denatured (18)
Depression (42)
Diabetes (268)
Diagnostics (6367)
Digital health (18)
Diversity (8)
Diversity, equity & inclusion (44)
Drug discovery (120)
Drug pricing (98)
Drug shortages (25)
Duchenne muscular dystrophy (93)
Earnings (86559)
Editorial (36)
Employer branding (21)
Employer resources (146)
Events (112328)
Executive appointments (718)
FDA (17419)
Featured Employer (47)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (7)
Funding (746)
Gene editing (103)
Generative AI (19)
Gene therapy (299)
GLP-1 (704)
Government (4414)
Grass and pollen (4)
Guidances (55)
Healthcare (18814)
Huntington's disease (23)
IgA nephropathy (27)
Immunology and inflammation (114)
Indications (29)
Infectious disease (2730)
Inflammatory bowel disease (136)
Inflation Reduction Act (8)
Influenza (51)
Intellectual property (96)
Interviews (311)
IPO (16507)
IRA (40)
Job creations (3630)
Job search strategy (1422)
Kidney cancer (10)
Labor market (38)
Layoffs (465)
Leadership (16)
Legal (7909)
Liver cancer (75)
Lung cancer (320)
Lymphoma (153)
Machine learning (7)
Management (58)
Manufacturing (302)
MASH (66)
Medical device (13373)
Medtech (13378)
Mergers & acquisitions (19452)
Metabolic disorders (678)
Multiple sclerosis (79)
NASH (16)
Neurodegenerative disease (88)
Neuropsychiatric disorders (27)
Neuroscience (1907)
NextGen: Class of 2025 (6512)
Non-profit (4480)
Northern California (2664)
Now hiring (39)
Obesity (361)
Opinion (204)
Ovarian cancer (75)
Pain (85)
Pancreatic cancer (83)
Parkinson's disease (148)
Partnered (21)
Patents (231)
Patient recruitment (108)
Peanut (46)
People (57287)
Pharmaceutical (63)
Pharmacy benefit managers (18)
Phase I (20549)
Phase II (29051)
Phase III (21648)
Pipeline (1178)
Policy (137)
Postmarket research (2563)
Preclinical (8735)
Press Release (64)
Prostate cancer (106)
Psychedelics (30)
Radiopharmaceuticals (246)
Rare diseases (378)
Real estate (5907)
Recruiting (65)
Regulatory (22269)
Reports (46)
Research institute (2320)
Resumes & cover letters (349)
Rett syndrome (5)
RNA editing (5)
RSV (42)
Schizophrenia (68)
Series A (129)
Series B (84)
Service/supplier (11)
Sickle cell disease (52)
Southern California (2284)
Special edition (14)
Spinal muscular atrophy (147)
Sponsored (29)
Startups (3575)
State (2)
Stomach cancer (13)
Supply chain (68)
Tariffs (37)
The Weekly (29)
United States (22926)
Vaccines (684)
Venture capitalists (41)
Weight loss (231)
Women's health (35)
Worklife (15)
Date
Today (157)
Last 7 days (850)
Last 30 days (2669)
Last 365 days (32899)
2025 (10483)
2024 (35218)
2023 (40076)
2022 (51174)
2021 (55711)
2020 (54083)
2019 (46540)
2018 (35019)
2017 (32110)
2016 (31480)
2015 (37552)
2014 (31318)
2013 (26345)
2012 (28570)
2011 (29263)
2010 (27328)
Location
Africa (718)
Alabama (53)
Alaska (7)
Arizona (231)
Arkansas (13)
Asia (37833)
Australia (6184)
California (6075)
Canada (2004)
China (520)
Colorado (265)
Connecticut (272)
Delaware (146)
Europe (81222)
Florida (904)
Georgia (204)
Idaho (57)
Illinois (528)
India (25)
Indiana (306)
Iowa (11)
Japan (159)
Kansas (104)
Kentucky (23)
Louisiana (10)
Maine (62)
Maryland (886)
Massachusetts (4530)
Michigan (216)
Minnesota (388)
Mississippi (2)
Missouri (81)
Montana (27)
Nebraska (25)
Nevada (63)
New Hampshire (63)
New Jersey (1712)
New Mexico (28)
New York (1728)
North Carolina (961)
North Dakota (8)
Northern California (2664)
Ohio (202)
Oklahoma (14)
Oregon (34)
Pennsylvania (1369)
Puerto Rico (12)
Rhode Island (33)
South America (1096)
South Carolina (22)
South Dakota (1)
Southern California (2284)
Tennessee (101)
Texas (899)
Utah (180)
Virginia (143)
Washington D.C. (61)
Washington State (549)
West Virginia (3)
Wisconsin (53)
698,591 Results for "chemocentryx inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Deals
AMGEN SUCCESSFULLY COMPLETES ACQUISITION OF CHEMOCENTRYX
Amgen (NASDAQ: AMGN) today announced that it has successfully completed its previously announced acquisition of ChemoCentryx, Inc. (NASDAQ: CCXI).
October 20, 2022
·
14 min read
Deals
AMGEN TO ACQUIRE CHEMOCENTRYX FOR $4 BILLION IN CASH
Amgen (NASDAQ: AMGN) and ChemoCentryx, Inc., today announced that the companies have entered into a definitive agreement under which Amgen will acquire ChemoCentryx for $52 per share in cash, representing an enterprise value of approximately $3.7 billion.
August 4, 2022
·
16 min read
Business
ChemoCentryx Announces Changes to its Board of Directors
ChemoCentryx, Inc., announced changes to the composition of its Board of Directors.
May 31, 2022
·
4 min read
Business
ChemoCentryx Cancels Second Quarter 2022 Financial Results Conference Call
ChemoCentryx, Inc., (Nasdaq: CCXI), today announced the cancellation of its second quarter 2022 financial results conference call scheduled for Tuesday, August 9, 2022, at 5:00 p.m. ET.
August 9, 2022
·
7 min read
Business
ChemoCentryx Announces Appointment of Jennifer L. Herron to Board as Independent Director
ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Jennifer L. Herron has been appointed to the Board as an independent director, effective June 28, 2022.
July 5, 2022
·
4 min read
Biotech Bay
ChemoCentryx Announces Abstracts at June Rheumatology, Oncology and Nephrology Conferences
ChemoCentryx, Inc., (Nasdaq: CCXI), today announced upcoming abstract presentations at three key medical conferences taking place in June, which highlight TAVNEOS® (avacopan).
May 31, 2022
·
8 min read
Business
ChemoCentryx to Hold Second Quarter 2022 Financial Results Conference Call on Tuesday, August 9, 2022
ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the Company’s second quarter 2022 financial results will be released after market close on Tuesday, August 9, 2022.
August 2, 2022
·
2 min read
Biotech Bay
ChemoCentryx Announces Presentations at the 2022 American Society of Nephrology and American College of Rheumatology Annual Meetings
ChemoCentryx, Inc., (Nasdaq: CCXI), today announced planned presentations covering TAVNEOS® (avacopan), an orally administered selective complement 5a receptor (C5aR) inhibitor, at the American Society of Nephrology (ASN) Kidney Week 2022 and American College of Rheumatology (ACR) Convergence 2022 annual meetings taking place in November.
October 17, 2022
·
10 min read
Business
ChemoCentryx Reports First Quarter 2022 Financial Results and Recent Highlights
ChemoCentryx, Inc., announced financial results for the first quarter ended March 31, 2022 and provided an overview of recent corporate highlights.
May 5, 2022
·
16 min read
Biotech Bay
ChemoCentryx Announces TAVNEOS® (avacopan) Presentations at Upcoming Medical Conferences
ChemoCentryx, Inc., (Nasdaq: CCXI), today announced planned poster presentations at three upcoming medical conferences taking place in August and September, which highlight TAVNEOS ® (avacopan), an orally administered selective complement 5a receptor (C5aR) inhibitor, and its role in ANCA-associated vasculitis, as well as the role of C5a and C5aR in severe hidradenitis suppurativa (HS) and lupus nephritis (LN).
August 24, 2022
·
8 min read
1 of 69,860
Next
